🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Industrials Sector SEC Filings — March 13, 2026

Across 50 SEC filings for the USA S&P 500 Industrials intelligence stream (though spanning financials, energy, healthcare), bank 10-Ks dominate with resilient growth: ~12 banks averaged 4.5% YoY asset growth, 12% YoY NII increase, and 20bps NIM expansion (e.g., Red River +25% net income, Princeton +82%), offset by rising NPAs/provisions in 4 cases (avg +200%). Industrials shine with Venture Global's landmark $20.7B CP2 LNG financing (Phase 2 FID $8.6B, no equity needed, targeting 100+ MTPA capacity), Ducommun's record $824.7M revenue (+49% stock gain under VISION 2027), and ArcBest's $4B revenue/$86M returns despite freight weakness. Capital allocation trends positive: 5 dividends (GIII $0.10, Designer $0.05), buybacks (First Northern 1M shares thru Apr'26), stock div (First Northern 5% payable 3/25). Forward-looking catalysts include Better Home's Q1'26 loan vol guide $1.4-1.55B (post +56% YoY Q4), Tonix cash runway to Q1'27, and proxy meetings clustered Apr-May'26. Mixed sentiment (60% mixed/neutral) signals stability but credit watch; overweight NII-expanders like Fidelity D&D (+16.7% NII), avoid NPA outliers like Isabella (+553%). Portfolio implication: Industrials/financial hybrids offer defensive alpha via returns/M&A amid macro caution.

34 high priority 16 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 13, 2026

Across these 7 diverse SEC filings (primarily real estate, banking, pharma/consumer health despite energy stream context), overarching themes include mixed financial performance with modest revenue growth offset by widening losses, impairments, and operational pressures in real estate entities. Period-over-period trends reveal revenue increases (BRT +1.5% YoY to $97M, Copper lease income +2% YoY to $96M, John Marshall NII +18.6% YoY) but declining profitability (BRT FY net loss to $(11.9M) from $(9.8M), Copper net income -36% YoY to $47M, same-store NOI flat/declining across BRT/Copper). Real estate-focused filings (BRT x2, Copper, Kaanapali) dominate with portfolio expansions/sales, higher debt costs, and impairments, while banking (John Marshall) shows robust +24% YoY net income growth to $21.2M and Haleon delivers clean audits. Capital allocation leans toward share repurchases (BRT 321k shares) and dividends (maintained $0.25 Q at BRT, $0.30 at John Marshall), but no insider trading patterns noted. Critical developments like Bioxytran's impairments/leadership changes signal distress, while land sales (Kaanapali +$10.3M gain) and bank asset growth (+4.4% to $2.33B) offer pockets of strength. Market implications: Heightened caution on real estate amid NOI declines and debt maturities, selective opportunities in growing financials; portfolio-level trend of margin compression (e.g., Copper NOI -7%, BRT AFFO flat) suggests broader sector vulnerability.

6 high priority 1 medium 7 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 13, 2026

Across 50 SEC filings purportedly from S&P 500 Financials (though spanning diverse sectors including pharma, hospitality, REITs, and banks), overarching themes include mixed sentiment with revenue growth in 12/20 reporting companies averaging +16% YoY (e.g., ONE Group +19.7%, Emerald +16.2%, Jefferson Capital +41.6%) offset by Q4 weakness, widening net losses (9/20 cases), and expense surges (e.g., Tonix SG&A +119%). True financials like Red River Bancshares (+25% net income, NIM +14bps to 3.38%), First Northern (+4.8% NII, NIM +17bps), Republic Bancorp (NPS +12% to 73.4), and Jefferson Capital (+45.8% net income) show resilience amid deposit declines elsewhere. Capital allocation leans shareholder-friendly with buybacks (News Corp $1B program, Emerald $17.5M repurchased, First Northern 1M+ shares authorized) and dividends (Emerald doubled to $0.06/share, BRT $0.25 Q). Insider activity limited to routine Walmart 10b5-1 plans (e.g., McMillon 155k shares). Forward-looking guidance optimistic for 2026 (ONE Group +4-6% rev, Emerald +6-7%), but risks from auditor changes (Amplify material weakness), lawsuits (Scilex fraud claims), and M&A approvals (Signing Day closes March 16). Portfolio-level: margin expansion in banks (3/4 improved), but REITs/others flat NOI; actionable now on catalysts like March 16-18 events.

30 high priority 20 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 13, 2026

The 50 8-K filings from March 13, 2026, reveal a surge in financing activities (12+ cases), including credit expansions, note issuances, and debt-for-equity swaps, signaling robust liquidity amid stable economic conditions; energy firms dominate positive developments with accretive acquisitions and $20.7B+ project financings. Executive transitions affect 15+ companies (resignations/appointments), mostly neutral/mixed but clustered in tech/healthcare, potentially signaling churn without major disagreements. Capital allocation trends favor shareholders via $10M repurchases (HealthStream), buyback permissions ($50M AMC), and hedging (Vitesse 67% 2026 oil hedged at $64-67/Bbl), contrasting dilutive raises (Olenox Series C, Functional Brands exchanges). M&A/asset sales (7 cases) show mixed pro forma impacts, e.g., Kaanapali $10.3M gain but sales declines YoY. No widespread margin compression; instead, operational enhancements (Battalion 30 drilling locations added) and forward contracts (ETHZilla 12-13% yields). Highest materiality events (10/10: IF Bancorp merger delist, Venture Global FID) imply sector rotation to energy/LNG; watch fintech tokenization and REIT dispositions for alpha.

50 high priority 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 13, 2026

Across 20 SEC filings from the USA S&P 500 Technology stream (including adjacent financials/tech enablers), overarching themes include mixed financial performance in community banks with net interest margin (NIM) expansions averaging +20 bps YoY in 3/5 reporters offsetting non-interest income declines (e.g., Chemung -65.8%), aggressive capital returns via buybacks and dividends, positive proxy outcomes with strong approvals, and strategic M&A/debt issuances signaling growth confidence. Period-over-period trends show NII growth averaging +8% YoY (First Northern +4.8%, Chemung +17.7%, NorthEast -2%), but net income declines in 4/8 reporters (Chemung -36.2%, NorthEast -5.65%); tech highlights feature Salesforce's $25B debt-for-buybacks and Intuitive Surgical's leadership transition. Critical developments: Esquire-Signature $350M accretive merger (20-25% 2027 EPS acc.), Aditxt's $36M oncology acquisition, and MultiSensor AI's $60M ATM for growth capital. Portfolio-level patterns reveal shareholder-friendly capital allocation (buybacks in 3 firms, stock dividend), proxy successes (5/5 positive), but deposit declines (First Northern -7.3%) and revenue softness (RideNow -10.5% YoY) flag liquidity pressures. Tech sector shows conviction via debt-funded returns and M&A into AI/oncology, positioning for catalysts like Q3 2026 deal closes.

16 high priority 4 medium 20 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 13, 2026

Across 19 filings from NASDAQ-100 related entities, community banks dominate with mixed 2025 results: net income declined YoY in all three (First Northern flat assets, Chemung -36.2% to $15.1M due to $17.5M securities loss offset by NII +17.7%, NorthEast -5.65% to $44.4M with NIM contracting -37bps), though NIM expanded in two (+17bps First Northern, +50bps Chemung) amid deposit declines (-7.3% First Northern). Positive corporate governance shines with overwhelming AGM approvals (Adient, Applied Materials, Ducommun record $824.7M rev +49% stock gain), leadership transitions (Intuitive Surgical CEO change), and capital raises (Amazon $37B notes for $36.8B net proceeds, NexMetals cash +551% to $39.8M post $80M financing). Biotech M&A/licensing active (Aditxt $36M Ignite acquisition targeting $3B market, AC Immune Takeda deal up to $2.1B milestones). Capital allocation favors shareholders via repurchases (First Northern 1M+ shares thru Apr 2026), stock div (5% First Northern), retention RSUs/awards (Adient $500K, Optimum $9.4M DCAs). Portfolio trend: financials show resilient NII growth (avg +8.8% YoY) despite one-offs, tech/industrials bullish on strategy execution. Key implication: Favor banks with NIM expansion and buybacks; monitor biotech catalysts amid loss risks.

13 high priority 6 medium 19 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 13, 2026

Across 50 SEC filings from March 13, 2026, primarily regional banks and select energy/financial firms (despite DJ30 stream focus, data spans broader US blue-chips and mid-caps), FY2025 10-Ks reveal mixed resilience: 9/15 banks reported asset growth averaging 6-62% YoY (e.g., ChoiceOne +62%), NIM expansions in 7/15 (avg +20bps, e.g., Red River +14% to 3.38%), but provisions spiked sharply in outliers (ChoiceOne +2,367% to $14.8M). Energy sector shines with accretive M&A (Battalion Oil adds 30 drilling locations) and mega-financings (Venture Global $20.7B CP2 LNG FID). Capital allocation tilts shareholder-friendly (buybacks/dividends in CCEP €1B, First Northern 1M+ shares, Universal $0.105/share), amid neutral insider plans (Walmart exec 10b5-1 sales for diversification). Forward catalysts cluster in April-May AGMs (10+ meetings) and deadlines (Olenox registration Apr 11); sentiments mixed/neutral dominate (28/50), with positive outliers in growth stories. Portfolio implication: overweight regional banks with NIM tailwinds/strong ROE (Red River 12.58%), monitor provision risks; energy M&A offers alpha amid LNG demand.

38 high priority 12 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 13, 2026

Across 50 SEC filings for March 13, 2026, key themes include mixed FY2025 results with revenue growth averaging +15% YoY in reporting companies (e.g., ONE Group +19.7%, Emerald +16.2%, Tonix +30% product rev) offset by Q4 weakness and margin pressures in hospitality/REITs, alongside robust capital allocation via dividends (GIII $0.10/share, Emerald $0.015/share, First Northern 5% stock dividend) and buybacks (Emerald $17.5M repurchased, $25M remaining; News Corp $1B program). Energy sector shines with Venture Global's $20.7B CP2 LNG financing (no equity dilution) positioning it as top US exporter at 100+ MTPA, and Battalion Oil's accretive acquisition adding 30 drilling locations. Pharma/biotech shows launches (Tonix TONMYA) but high cash burn; banks/REITs mixed with NIM expansion (First Northern +17 bps to 3.77%) but deposit declines. Forward guidance optimistic in hospitality/events (ONE Group $840-855M rev 2026, Emerald $490-495M), while insider activity neutral (Walmart 10b5-1 plans for diversification). Portfolio-level: 6/10 detailed filers issued upbeat 2026 guidance, but 4/10 reported net losses widening YoY; M&A/acquisitions in 5 filings signal consolidation. Implications: Favor energy/infrastructure over cyclical hospitality amid quiet deposit growth in banks.

32 high priority 18 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 13, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (heavily skewed toward financials, retail/auto/entertainment), FY2025 results show mixed trends with robust revenue/NII growth averaging +30-50% YoY in outperformers like Jefferson Capital (+41.6%), Velocity Financial (+69% Q4 net income), and Better Home & Finance (+52% revenues), but widespread profitability erosion via compressed ROA/ROE (e.g., CHOICEONE ROA -31bps to 0.69%), exploding provisions (CHOICEONE +2367% to $14.8M), and rising expenses. Capital allocation leans bullish with buybacks (Ford 31.7M shares, CCEP €1B completed, Amazon/Salesforce debt-funded repurchases), stock dividends (First Northern 5%), and M&A (IF Bancorp merger delisting, Burke & Herbert board changes). Consumer discretionary standouts include Ford's anti-dilutive buyback, Walmart insider diversification plans (neutral), and Amazon's $37B notes for buybacks; entertainment sees director exits (Six Flags). Forward catalysts cluster in Q1-Q2 2026 (Better Home $1.4-1.55B Q1 volume, breakeven Q3), with risks from auditor changes (Amplify, Black Rock Coffee material weaknesses) and liquidity strains (Maris Tech substantial doubt). Portfolio implication: Favor growth financials with NIM expansion (First Northern +17bps, Fidelity D&D +16.7% NII) over deteriorating ones; monitor consumer buybacks for conviction.

36 high priority 14 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 13, 2026

Across 48 SEC filings from the USA S&P 500 Healthcare stream (with heavy financial sector overlap), overarching themes include mixed financial performance in regional banks with net interest margin (NIM) expansions averaging +50bps YoY in 5/9 reporting banks (e.g., ChoiceOne +66bps to 3.61%, Norwood +58bps to 3.49%) offset by ROE declines in 4/7 (avg -300bps) due to higher provisions and expenses; healthcare firms show leadership transitions signaling continuity (Cigna CEO change July 2026, Intuitive Surgical CEO April 2026). Period-over-period trends reveal revenue growth in 6/15 detailed firms (avg +25% YoY, e.g., Norwood NII +26%) but net income volatility (wins like Franklin +91%, losses like Harvard Bioscience -$56.7M due to $48M goodwill impairment). Capital allocation leans shareholder-friendly with buybacks (CCEP €1B completed, News Corp $1B ongoing, Franklin 6,500 shares repurchased) and dividends (NewtekOne $0.19/share Q2 2026, SAIC $0.37/share). Healthcare-specific signals include positive proxy sentiments for Abbott and Intuitive Surgical, while Scilex's lawsuit adds sector litigation risk. Portfolio-level: 12/48 mixed sentiment filings highlight integration/M&A pressures (Esquire-Signature $350M deal 20-25% accretive), with upcoming AGMs (April 2026 cluster) as catalysts. Implications: Favor NIM expanders with strong capital returns; monitor healthcare leadership for execution risks.

31 high priority 17 medium 48 total filings
· daily

Global High-Priority Regulatory Events — March 13, 2026

Across 50 filings in the Global High Priority Market Events stream (US SEC focus with global insolvency/takeover/regulatory themes), key themes include robust energy project financings and acquisitions contrasting with Indian insolvencies and mixed bank/REIT 10-K results; period-over-period trends show 7/15 10-Ks with revenue growth averaging +20% YoY (e.g., Perfect Corp +14.9%, SenesTech +20%) but 4 with declines averaging -11% (Quest -13.2%), NIM expansions in 3 banks (+14-37 bps), and portfolio expansions in BDCs/lenders. Critical developments feature Venture Global's $8.6B CP2 LNG FID (total $20.7B financing, +100 MTPA capacity), BlackRock's stake increase in Sammaan Capital (+0.06%), and multiple Indian insolvencies (Punj Lloyd, Shree Hanuman). Capital allocation highlights buybacks (CCEP €1B completed, First Northern repurchase program), dividends (5% stock dividend), and financings; insider patterns show institutional buying but key resignations (Greenpanel President, Nine Energy GC). Market implications point to energy export strength amid LNG demand, bank resilience despite deposit shifts, and distress opportunities in India, with catalysts like CoC meetings and IPOs driving near-term volatility.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 13, 2026

The IPO pipeline shows robust activity with 6 S-1 filings on March 13, 2026, dominated by SPACs (2/6), bank mutual-to-stock conversions (2/6), a microcap tech play, and a crypto ETF, highlighting diverse entry points into public markets amid limited traditional IPOs. No broad period-over-period financial trends available due to pre-IPO status, but common $10/share pricing in 4/6 filings signals standardized valuation approach for SPACs and banks versus Dravica's $0.03 outlier. Positive sentiment in CSB Financial contrasts with Dravica's negative going concern flag and JATT II's dilution risks, while neutrals dominate. Bank conversions emphasize depositor/plan priorities for subscription success, SPACs offer dry powder with 24-month windows, and niche plays like crypto staking add volatility. Portfolio implications favor monitoring bank conversions for stable liquidity events and SPACs for M&A catalysts, with cross-filing comparison revealing CSB's $14.55M proceeds potential outperforming Dravica's $120k micro-raise.

6 high priority 6 total filings
· daily

US Earnings Financial Results SEC Filings — March 13, 2026

Across 50 10-K and 10-Q filings from March 13, 2026, primarily US banks, financial services, investment vehicles, and select industrials/biotechs, overarching themes include resilient balance sheet growth in banking (avg assets +5% YoY across 20+ cos, loans +7% avg) with NIM expansions in 15/20 banks (avg +25bps YoY) but offset by rising provisions/NPAs in 8 cos. Non-bank financials and BDCs show strong portfolio ramps (e.g., investments +37% to 84 cos in one, net assets +132% in another) and revenue growth in outliers like Jefferson Capital (+42% revenues), while industrials/manufacturing face revenue declines (avg -8% YoY in 7 cos) amid margin compression. Capital allocation leans shareholder-friendly with buybacks/dividends in 12 cos (e.g., First Northern 1M+ shares thru Apr 2026, multiple dividend hikes), but mixed sentiment dominates (45/50 mixed/negative) signals caution on profitability deterioration (ROA/ROE down in 10 cos). Forward-looking catalysts include merger integrations (Esquire/Signature), patent risks (Vaxart Inavir 2036), and buyback/stock dividend dates. Portfolio-level: Banks outperform on NIM/ROE vs non-financials' EBITDA declines (avg -15% in 10 cos), highlighting defensive rotation into regional banks with strong capital returns amid deposit growth (+6% avg). Critical implication: Opportunities in outperforming banks (e.g., Red River ROE 12.6%) vs risks in provision-heavy lenders.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 13, 2026

Across 50 DEF 14A proxy filings, a dominant theme is leadership transitions in 12 companies (e.g., Crane Co, Cigna Group, KB Home, Intuitive Surgical, Bank of Hawaii), signaling board refreshment and succession planning amid strong 2025 performance highlights like record revenues at KB Home ($6.2B+), Ducommun ($824.7M), and ArcBest ($4.0B). Period-over-period trends show bullish outliers including NPS +12% YoY at Republic Bancorp to 73.4 (2.5x bank avg), Berkshire Hathaway +117% 5-yr return vs S&P 500 +96%, Myers Industries stock +72% vs S&P +18%, and GATX rail revenues +6% YoY with $333M NI; however, mixed signals from Edison's 40% CEO comp cuts due to wildfires and Owens Corning auditor fees -24% YoY to $9.8M. Capital allocation trends emphasize shareholder returns ($600M+ at KB Home, $86M at ArcBest), high insider ownership (68% at Rand Capital, 14.6% at Eagle), and governance enhancements like board diversity (55% at Owens Corning). Banking sector (14 filings) largely neutral with board size reductions (Red River to 8), while industrials/homebuilders (8 filings) skew positive with YoY growth. Market implications include proxy vote catalysts in April-May 2026 driving volatility, potential say-on-pay pushback, and opportunities in transitionary firms with aligned comp. Overall sentiment positive/neutral (42/50), with materiality clustered at 6-8/10 for growth leaders.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 13, 2026

Across 39 filings on US executive and director changes from March 13, 2026, a dominant theme is neutral-to-positive leadership stability with 18 resignations/retirements (mostly voluntary, age/policy-related, no disagreements), balanced by 15 new appointments/promotions of experienced executives, particularly CFOs and directors in finance/tech/energy sectors. CFO turnover is elevated (8 cases, including 3 interim appointments), signaling potential transition risks but proactive retention via equity grants/RSUs in 12 companies (e.g., options/RSUs vesting 2026-2028). Shareholder meetings (5 cases) showed strong approvals for directors/auditors but mixed say-on-pay/equity plan votes (e.g., Veru 975k against equity increase, F5 16M against incentive plan), with sentiments neutral (22), positive (10), mixed (4), negative (1), and materiality averaging 6/10. Enriched data reveals positive capital allocation via performance-tied incentives (e.g., USPH 2026 EBITDA targets $101.6M-$108.24M, up from implied prior), hedging supporting dividends (Vitesse 67% 2026 oil hedged at $64-67/Bbl), but limited YoY financial trends due to 8-K focus; no broad margin/revenue declines noted. Portfolio-level, small/mid-caps show higher turnover (25/39), while larger caps emphasize retention bonuses (Waste Management $1M transition bonus). Market implications: monitor CFO transitions for execution risks, but bullish on insider-aligned equity grants signaling conviction amid stable guidance.

39 high priority 39 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 13, 2026

Across 41 8-K filings in the USA Corporate Distress & Bankruptcy stream, dominant themes include aggressive financing maneuvers (e.g., credit amendments, ATM offerings, debt issuances totaling billions) to bolster liquidity amid scattered distress signals like Nasdaq/NYSE listing deficiencies in 4 companies and debt-for-equity swaps indicating balance sheet strains. No broad period-over-period declines are quantified, but inferred trends show 6/41 companies executing dilutive equity raises or exchanges (e.g., NextNRG's $1.75M debt-for-3.18M shares), contrasting with positive capital raises like Venture Global's $8.6B CP2 Phase 2 FID. Critical developments feature imminent delistings (Bio Green Med's preferred stock suspension March 23, 2026) and compliance grace periods (Talphera until Sept 7, 2026; Azitra until Apr 1, 2027), signaling heightened bankruptcy risks for microcaps in pharma/biotech. Portfolio-level patterns reveal sector-agnostic distress financing, with energy/oil (Battalion, 1606 Corp) pursuing accretive acquisitions while tech/pharma (Azitra, Talphera) face equity erosion. Overall, 22/41 neutral/positive sentiments mask underlying pressures, urging vigilance on dilution and listing catalysts for short-term trading opportunities.

41 high priority 41 total filings
· daily

US SEC Trading Suspension Halt Orders — March 13, 2026

Four small-cap companies across healthcare and biotech sectors reported critical US exchange listing compliance failures in March 2026, highlighting a portfolio-level trend of microcap distress with 3/4 filings showing negative sentiment and persistent financial weaknesses like low bid prices, equity deficiencies, and MVPHS shortfalls. No positive YoY/QoQ revenue or margin trends evident; instead, Azitra disclosed net losses across five consecutive fiscal years ended Dec 31, 2025, with stockholders' equity at $3.8M versus $6.0M required, signaling ongoing deterioration from prior $4.0M deficiency. Bio Green Med faces imminent preferred stock delisting and trading suspension on Mar 23, 2026, post-180-day compliance failure from Sep 11, 2025 notice, while Talphera's bid price < $1.00 for 30 days triggers 180-day clock to Sep 7, 2026. Sadot Group resolved a voting rights violation via amendment, marking the sole mixed-positive outcome. Market implications include elevated delisting risks, potential reverse splits, OTC migrations, and short-term price volatility, with no insider buying or dividend hikes to signal conviction—watch for cascading suspensions in weak microcaps.

4 high priority 4 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 13, 2026

Across 39 filings on USA Board Room Changes from March 13, 2026, a dominant theme is elevated C-suite and board turnover, with 12 CFO/EVP Finance-related changes (resignations in Sprout Social, Waste Management, Wheeler REIT; appointments in CONMED, Hexcel, Orgenesis, Mitesco) signaling potential execution risks amid interim leadership in multiple firms. Director resignations/retirements affected 14 companies (e.g., Nine Energy, Vitesse, Six Flags, Goldman Sachs), often voluntary or age-related, balanced by 10 new appointments of experienced executives/directors (e.g., Avidbank, Hexcel CFO from Axcelis, Cyber App Solutions). Equity incentives surged as retention tools, with grants/RSUs/DCAs in 11 firms (Forward Industries options, Adient $500k RSU, Paymentus RSUs, Optimum $9.375M DCAs), reflecting alignment but mixed AGM votes (Veru 975k against equity plan, F5 16.1M against incentives). No broad YoY/QoQ financial declines noted, but Vitesse's 67% 2026 oil production hedged at $64-67/Bbl supports dividends positively; capital allocation leans toward reinvestment via incentives over buybacks/dividends. Portfolio-level pattern: Higher materiality (7-8/10) events cluster in tech/SaaS (Sprout, Asana) and finance (Waste Mgmt, Avidbank), implying sector-specific leadership refreshes for growth/turnarounds. Market implications: Bullish for firms with proven hires, bearish for abrupt exits without successors, creating near-term volatility opportunities.

39 high priority 39 total filings
· daily

US Merger & Acquisition SEC Filings — March 13, 2026

The 13 filings reveal a surge in SPAC activity with 7/13 involving blank check companies, including 3 IPOs/pricings (Kensington $230M, SUMA $150M) and extensions/deposit (Inception $12k for 1-month to April 13), signaling robust capital raising for M&A amid a 24-36 month combination windows. M&A completions dominate with IF Bancorp merger finalized at $26.40/share cash (delisting March 13), Aditxt's $36M oncology acquisition, and asset sales like Kaanapali's $19.9M land ($10.3M gain) and Moody REIT's $18.85M hotel disposition, though pro forma sales declines noted in 2 cases. Mixed sentiment in 3 filings highlights pro forma deteriorations (New Mountain net assets -3% to $1.153B, realized losses widened to $155M), but overall positive tone in 6/13 with no YoY/QoQ revenue declines beyond isolated pro formas (-$123k 2024 sales for Kaanapali). No insider trading or capital allocation shifts reported across filings, but forward-looking catalysts cluster in March (delistings, trading starts, closings). Portfolio-level trend: Elevated M&A velocity in SPACs/tech/healthcare vs quieter real estate dispositions; implications include heightened takeover premiums and de-SPAC opportunities, with $230M+ trust accounts positioning energy/tech targets.

13 high priority 13 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 13, 2026

Overnight SEC filings for March 13, 2026, reveal a mix of FY2025 10-K annual reports dominating (e.g., banks, pharma, REITs, BDCs), with period-over-period trends showing resilient revenue growth in select pharma/biotech (avg +25% YoY for Tonix, SenesTech, Vaxart) and banks (Red River net income +25% YoY, First Northern NII +4.8%), but widespread margin pressures and operating losses in industrials/REITs (Quest revenue -13% YoY, BRT NOI flat). Capital allocation leans positive with buybacks (News Corp $1B program, First Northern 1M+ shares authorized), dividends (BRT AFFO +3%), and financings (Karman +$100M revolver, Olenox $810k preferred). Auditor changes (Amplify material weakness) and litigation (Scilex fraud suit) flag risks, while M&A/acquisitions (Battalion 7k acres all-stock) and guidance (Emerald FY26 revenue $490-495M) offer catalysts. Sector themes include banking NIM expansion (Red River +14 bps to 3.38%) vs deposit declines, BDC portfolio ramps (Unknown Co net assets +huge from inception), and mixed pharma commercialization ramps amid high cash burn. Portfolio-level: 12/20 10-Ks mixed sentiment, cash positions strengthened in 8/15 reporting cos (e.g., Tonix to $207M), signaling near-term runway but watch for Q1 2026 guidance shifts. Actionable: Favor banks/BDCs with NIM/ROE gains, avoid litigation-exposed biotech.

35 high priority 15 medium 50 total filings